Current Report Filing (8-k)
July 25 2018 - 12:19PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 23, 2018
MEDIFIRST
SOLUTIONS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-178825
|
|
27-3888260
|
State or other jurisdiction
|
|
Commission File Number
|
|
IRS Employer
|
incorporation
|
|
|
|
Identification No.
|
4400 Route 9 South, Suite 1000, Freehold,
|
|
NJ 07728
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (732)-786-8044
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
|
Section
5-
|
Corporate
Governance and Management
|
|
Item
5.03
|
Amendment
to Articles of Incorporation or Bylaws; Change in Fiscal year
|
Effective
July 23, 2018, the Company completed a 1-for-1,000 reverse stock split of its issued and outstanding common stock. The number
of shares of common stock issued and outstanding post- reverse stock split is 1,404,073. All fractional shares have been rounded
up to the next whole share. There is no reduction in the number of the Company’s shareholders of record. The Company’s
trading symbol will be MFSTD. The symbol will revert back to MFST twenty (20) business days after the effective date.
|
Item
7.01
|
Regulation
FD Disclosure
|
The
Company incorporates by reference the disclosures in Item 5.03. Included with this report is a press release announcing the reverse
stock split and other corporate information.
|
Section
9-
|
Financial
Statements and Exhibits
|
|
Item
9.01
|
Financial
Statements and Exhibits
|
Attached
to this Report as Exhibit 99.1 is the press release referred to in Item 7.01 of this report.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MEDIFIRST SOLUTIONS INC.
|
|
|
Dated: July 25, 2018
|
By:
|
/s/
Bruce Schoengood
|
|
|
President & Chief Executive Officer
|
2